Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | GENERAL COUNSEL & CORP SEC | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,598 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 627 · Balance 20,598 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2025 Filed Aug 15, 2025 20:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 13,712 | $15.00 | $205,680.00 |
DisclosureSEC source: 0001415889-25-022074 · form4-08152025_080840.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,631 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F2 · balance_after: The reported total includes an aggregate 1,778 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008709 · form4-03202025_100334.xml · derivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2029-03-20 F5 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001415889-25-008709 · form4-03202025_100334.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2035-03-19 F4 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,945 | $8.27 | $16,085.15 |
DisclosureSEC source: 0001415889-25-008709 · form4-03202025_100334.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,565 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,266 | $8.67 | $19,646.22 |
DisclosureSEC source: 0001415889-25-008709 · form4-03202025_100334.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,510 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008367 · form4-03182025_080351.xml · derivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008367 · form4-03182025_080351.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common Stock · 7,475 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008367 · form4-03182025_080351.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008367 · form4-03182025_080351.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 825 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,552 | $12.99 | $20,164.05 |
DisclosureSEC source: 0001415889-24-028929 · form4-12112024_091251.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,476 F3 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.24 per share, inclusive. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 12,114 | $13.69 | $165,814.01 |
DisclosureSEC source: 0001415889-24-028929 · form4-12112024_091251.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,028 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $14.22 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote (4). Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 00:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,696 | $12.78 | $123,890.64 |
DisclosureSEC source: 0001415889-24-028891 · form4-12112024_121243.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,142 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028398 · form4-12052024_091203.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantPerformance Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028398 · form4-12052024_091203.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2025-12-03 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028398 · form4-12052024_091203.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:14 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 33,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028071 · form4-12032024_091216.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,357 Underlying: Common Stock · 33,927 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: 33,927 restricted stock units vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:14 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 33,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028071 · form4-12032024_091216.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,313 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,599 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-014082 · form4-05222024_080500.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,801 Underlying: Common Stock · 8,599 shares Expires 2032-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 8,599 | $15.04 | $129,327.24 |
DisclosureSEC source: 0001415889-24-014082 · form4-05222024_080500.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,598 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 8,599 | $7.07 | $60,794.93 |
DisclosureSEC source: 0001415889-24-014082 · form4-05222024_080500.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:14 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 100 | $13.81 | $1,381.00 |
DisclosureSEC source: 0001415889-24-009532 · form4-04012024_080416.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,598 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:14 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,026 | $13.19 | $66,286.91 |
DisclosureSEC source: 0001415889-24-009532 · form4-04012024_080416.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,698 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.62 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:37 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015998 · form4-06072024_080658.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:37 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015998 · form4-06072024_080658.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-03-26 F1 · derivative.exercise_date: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,349 | $6.10 | $14,325.61 |
DisclosureSEC source: 0001415889-24-008681 · form4-03202024_120354.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,724 F2 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008681 · form4-03202024_120354.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,425 Underlying: Common Stock · 7,475 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008681 · form4-03202024_120354.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,598 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 46,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,284 Underlying: Common Stock · 46,284 shares Expires 2025-12-01 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: 33,927 restricted stock units will vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 121,100 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,100 shares Expires 2032-03-14 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 121,100 shares of Common Stock of the Issuer and in exchange issued to the reporting person 37,843 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $59.84 | Not disclosed |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2031-02-15 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,441 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/4th of the total award on February 16, 2022, and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:45 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,948 | $13.48 | $26,252.22 |
DisclosureSEC source: 0001209191-23-039428 · doc4.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 22, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.21 to $13.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:37 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 29,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019676 · doc4.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900 Underlying: Common Stock · 29,900 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:37 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 44,800 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019676 · doc4.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,800 Underlying: Common Stock · 44,800 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.